Cymbalta Withdrawal Litigation Unsealed Documents
Declassified court documents obtained by Baum Hedlund during the course of the Cymbalta Withdrawal Litigation show that Eli Lilly and Company (the manufacturer of Cymbalta) was well aware of Cymbalta’s withdrawal risks, that they occur frequently and can be quite severe. Instead of being upfront about the risk, Lilly hid behind a misleading label, making it appear the risk was rare and symptoms mild.
Cymbalta Withdrawal Expert Trial Testimony and Exhibits
Expert Witness, Dr. Joseph Glenmullen, explains how Lilly obscured the risk of Cymbalta withdrawal.
- Exhibit 001: Dr. Glenmullen Expert Witness Testimony
- Exhibit 011: Clinical Report Form – Fluoxetine v. Sertraline and Paroxetine in Major Depression
- Exhibit 022: Highlights of Prescribing Information for Cymbalta
- Exhibit 069: Duloxetine v. Venlafaxine Extended Release in Treatment of Major Depressive Disorder
- Exhibit 070: Cymbalta: Supportive Optional Document to Duloxetine Core Data Sheet Pre-Read Based on Clinical Trial Data in Adult Population
- Exhibit 078: Journal of Clinical Psychiatry Supplement – Antidepressant Discontinuation Syndrome: Update on SSRIs 1997
- Exhibit 093: Journal Affective Disorders – Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder 2005
- Exhibit 110: Table 4.138: Treatment-Emergent Adverse Events MedDRA
- Exhibit 111: Table 4.35: Treatment-Emergent Adverse Events AMDP-5
- Exhibit 112: Table 4.20: Treatment-Emergent-Adverse-Events-AMDP-5
- Exhibit 119: Biological Psychiatry – SSRI Discontinuation Syndrome: A Randomized Clinical Trial 1998
- Exhibit 151: Illustration Brain Cell Sending and Receiving SSRI Messages (1 of 2)
- Exhibit 152: Illustration Brain Cell Sending and Receiving SSRI Messages (2 of 2)
- Exhibit 661: Journal of Clinical Psychiatry – Prospective Studies of Adverse Events Related to Antidepressant Discontinuation 2006
Cymbalta Withdrawal Factual Summary and Exhibits
These court documents show Lilly’s knowledge of Cymbalta withdrawal.
- Appendix A: Plaintiffs’ Proposed Facts – Hagan-Brown, Ali v. Eli Lilly
- Exhibit 01: Deposition of Michael J. Detke
- Exhibit 02: Walter Deberdt Email Re: Comments on SUI Clinical Expert Report
- Exhibit 03: Journal Clinical Psychiatry – Antidepressant Discontinuation Syndrome: Update on SSRIs (1997)
- Exhibit 04: SSRI Discontinuation Syndrome: A Randomized Clinical Trial (1998)
- Exhibit 05: Ali v. Eli Lilly Defendant’s Responses to Plaintiff’s Amended First Set of Requests for Admission
- Exhibit 06: Brintnall & Nicolini – Prozac Pyramid Positioning / Message Development Research
- Exhibit 07: Eli Lilly U.S. Strategic Pricing Study – Cymbalta (2002)
- Exhibit 08: Lilly Internal Email – Perahia, Detke, Wohlreich RE: Discontinuation Data
- Exhibit 09: Deposition of Madelaine Wohlreich (4/29/2015)
- Exhibit 10: Cymbalta Patient Segmentation Study (2004)
- Exhibit 11: Saavedra v. Eli Lilly – Declaration of Sarah Helgeson (2013)
- Exhibit 12: Study: Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder (2005)
- Exhibit 13: Ali v. Eli Lilly – Defendants’ Responses to Plaintiff’s First Set of Requests for Production of Documents
- Exhibit 14: Hagan-Brown v. Eli Lilly – Defendants’ Responses to Plaintiff’s First Set of Requests for Production of Documents
- Exhibit 15: Letter – Covington to Baum Hedlund RE: Hagan-Brown, Ali v Eli Lilly (March 2015)
- Exhibit 16: Cymbalta Annex I – Summary of Product Characteristics
- Exhibit 17: Side by Side Comparison of U.S. and European Labels for Cymbalta
- Exhibit 18: Deposition of Sharon Hoog
- Exhibit 20: Deposition of Dr. Navera Ahmed
- Exhibit 21: Deposition of Matt Kuntz
- Exhibit 22: Lilly Internal Email – Williams, Detke RE: Withdrawal Scale for Duloxetine
- Exhibit 23: Duloxetine vs. Venflaxine Extended Release in the Treatment of Major Depressive Disorder (2002-2003)
- Exhibit 24: Deposition of Madelaine Wohlreich (4/30/2015)
- Exhibit 25: Boehringer Ingelheim Clinical Trial Protocol Revision A (June 2004)
- Exhibit 26: Lilly Clinical Report Form – Fluoxetine v. Sertraline and Paroxetine in Major Depression: Comparison of Discontinuation-Emergent Symptoms
- Exhibit 27: Table 4.35 Treatment-Emergent Adverse Events Collected by AMDP-5
- Exhibit 28: Table 4.20 Treatment-Emergent Adverse Events Collected by AMDP-5
- Exhibit 29: Lilly Internal Email – Perahia, Spencer, Brannan RE: HMBU Taper Period (Oct. 2002)
- Exhibit 30: Clinical Study Report: Duloxetine Hydrochloride 60mg or 120mg Once Daily Compared with Placebo in Patients with Generalized Anxiety Disorder
- Exhibit 31: Lilly Internal Email – Wang, Bump, Sakai, Detke, Stephens RE: Follow-up on PLR Meeting
- Exhibit 32: Deposition of Christine Phillips PhD
- Exhibit 33: Memo From Division of Medication Errors and Technical Support (2007)
- Exhibit 34: Letter from Dr. Glenmullen to Matthew Leckman (Sept. 2014)
- Exhibit 35: Dr. Glenmullen Addendum to Cymbalta Withdrawal General Causation Report May 2015
- Exhibit 36: Louis Morris PhD Expert Report Cymbalta Discontinuation Litigation
- Exhibit 37: Louis Morris PhD Supplemental Expert Report Cymbalta Discontinuation Litigation
- Exhibit 38: Deposition of Dr. Michael Clark
- Exhibit 39: Guidance for Industry Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products – Content and Format
- Exhibit 40: Lilly Internal Email – Lee, Perahia RE: Question on DEAE’s (Dec. 2010)
- Exhibit 41: Lilly Internal Email – Ziering, Perahia RE: Duloxetine/Cymbalta Withdrawal Question (Oct. 2006)
- Exhibit 44: Lilly Internal Email – Miles, Detke, Kajdasz, Desaiah RE: Resubmitted. Your Review Required Again for Disclosure Approval Request
- Exhibit 45: Study: A Randomized, Double-Blind Comparison of Duloxetine and Venlafaxine in the Treatment of Patients with Major Depressive Disorder (2008)
- Exhibit 46: Declaration of Dr. Joseph Glenmullen (Aug. 2013)
Our Case Results
-
$265 Million Settlement Fatal Train Crash
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
-
$3.5 Million Settlement Fatal Train Crash
Wisner Baum secured a $3.5 million settlement on behalf of an individual who died on a train.
-
$2 Million Settlement Fatal Train Crash
Wisner Baum obtained a $2 million settlement on behalf of a passenger who died on a train.
-
$2.8 Million Settlement Wrongful Death
Wisner Baum obtained a $2.8 million wrongful death settlement for a train passenger.
Client-Focused Representation
REVIEWS & TESTIMONIALS
We believe our track record speaks for itself. But you don’t have to take our word for it. See what our clients have to say about working with us.
-
"I Can’t Imagine a Better Law Firm"
Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.
- Best Law Firms Survey -
"They Are About Changing the Systems..."
Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.
- Kim Witczak -
"Top Legal Minds in the Country"
The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.
- From Best Lawyers® Best Law Firms
